Stock Track | INNOGEN-B Plummets 5.79% Intraday as FY2025 Loss Widens 95.4% on Surging R&D and Commercial Expenses

Stock Track03-24

INNOGEN-B (02591) shares plummeted 5.79% during Tuesday's intraday trading session, following the release of the company's first post-IPO annual results for the fiscal year 2025.

The pharmaceutical company reported its maiden revenue of RMB131.51 million, generated from the launch of its core diabetes product Efsubaglutide Alfa. However, the net loss attributable to shareholders widened significantly to RMB341.36 million, representing a 95.4% increase compared to the previous year. The substantial loss expansion was primarily driven by a more than doubling of research and development expenses to RMB205.78 million and a dramatic surge in selling and distribution expenses to RMB176.65 million as the company scaled up commercial activities.

Despite achieving National Reimbursement Drug List inclusion for its diabetes treatment and progressing with obesity clinical trials, investors reacted negatively to the ballooning costs and continued heavy investment phase. The company also announced plans to enter the Latin America market as part of its global expansion strategy.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1188306372?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-24 09:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1188306372","market":"nz","top_or_hot":-1,"title":"Stock Track | INNOGEN-B Plummets 5.79% Intraday as FY2025 Loss Widens 95.4% on Surging R&D and Commercial Expenses","media":"Stock Track","content":"<p>INNOGEN-B (02591) shares plummeted 5.79% during Tuesday's intraday trading session, following the release of the company's first post-IPO annual results for the fiscal year 2025.</p><p>The pharmaceutical company reported its maiden revenue of RMB131.51 million, generated from the launch of its core diabetes product Efsubaglutide Alfa. However, the net loss attributable to shareholders widened significantly to RMB341.36 million, representing a 95.4% increase compared to the previous year. The substantial loss expansion was primarily driven by a more than doubling of research and development expenses to RMB205.78 million and a dramatic surge in selling and distribution expenses to RMB176.65 million as the company scaled up commercial activities.</p><p>Despite achieving National Reimbursement Drug List inclusion for its diabetes treatment and progressing with obesity clinical trials, investors reacted negatively to the ballooning costs and continued heavy investment phase. The company also announced plans to enter the Latin America market as part of its global expansion strategy.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | INNOGEN-B Plummets 5.79% Intraday as FY2025 Loss Widens 95.4% on Surging R&D and Commercial Expenses</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | INNOGEN-B Plummets 5.79% Intraday as FY2025 Loss Widens 95.4% on Surging R&D and Commercial Expenses\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-24 09:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>INNOGEN-B (02591) shares plummeted 5.79% during Tuesday's intraday trading session, following the release of the company's first post-IPO annual results for the fiscal year 2025.</p><p>The pharmaceutical company reported its maiden revenue of RMB131.51 million, generated from the launch of its core diabetes product Efsubaglutide Alfa. However, the net loss attributable to shareholders widened significantly to RMB341.36 million, representing a 95.4% increase compared to the previous year. The substantial loss expansion was primarily driven by a more than doubling of research and development expenses to RMB205.78 million and a dramatic surge in selling and distribution expenses to RMB176.65 million as the company scaled up commercial activities.</p><p>Despite achieving National Reimbursement Drug List inclusion for its diabetes treatment and progressing with obesity clinical trials, investors reacted negatively to the ballooning costs and continued heavy investment phase. The company also announced plans to enter the Latin America market as part of its global expansion strategy.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02591","symbol_name":"银诺医药-B","start_time":0,"source_url":"","article_id":"1188306372","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1188306372","pubTimestamp":1774316538,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"INNOGEN-B (02591) shares plummeted 5.79% during Tuesday's intraday trading session, following the release of the company's first post-IPO annual results for the fiscal year 2025.The pharmaceutical...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02591":"银诺医药-B"},"translate_title":"个股追踪|英诺健-B盘中暴跌5.79%，2025财年亏损扩大95.4%，原因是研发和商业开支激增","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02591":1},"content_text":"INNOGEN-B (02591) shares plummeted 5.79% during Tuesday's intraday trading session, following the release of the company's first post-IPO annual results for the fiscal year 2025.The pharmaceutical company reported its maiden revenue of RMB131.51 million, generated from the launch of its core diabetes product Efsubaglutide Alfa. However, the net loss attributable to shareholders widened significantly to RMB341.36 million, representing a 95.4% increase compared to the previous year. The substantial loss expansion was primarily driven by a more than doubling of research and development expenses to RMB205.78 million and a dramatic surge in selling and distribution expenses to RMB176.65 million as the company scaled up commercial activities.Despite achieving National Reimbursement Drug List inclusion for its diabetes treatment and progressing with obesity clinical trials, investors reacted negatively to the ballooning costs and continued heavy investment phase. The company also announced plans to enter the Latin America market as part of its global expansion strategy.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1188306372","isCrawlerRequest":true}